Overview

A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease

Status:
Withdrawn
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess efficacy, safety and tolerability of 2 dose regimens of certolizumab pegol
Phase:
Phase 3
Details
Lead Sponsor:
UCB Biopharma SRL
Treatments:
Adalimumab
Certolizumab Pegol